Research ArticleClinical Investigations
Everolimus Reduces 89Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors
Sophie J. van Asselt, Sjoukje F. Oosting, Adrienne H. Brouwers, Alfons H.H. Bongaerts, Johan R. de Jong, Marjolijn N. Lub-de Hooge, Thijs H. Oude Munnink, Helle-Brit Fiebrich, Wim J. Sluiter, Thera P. Links, Annemiek M.E. Walenkamp and Elisabeth G.E. de Vries
Journal of Nuclear Medicine July 2014, 55 (7) 1087-1092; DOI: https://doi.org/10.2967/jnumed.113.129056
Sophie J. van Asselt
1Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
2Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Sjoukje F. Oosting
1Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Adrienne H. Brouwers
3Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Alfons H.H. Bongaerts
1Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
4Department of Radiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; and
Johan R. de Jong
3Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Marjolijn N. Lub-de Hooge
3Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
5Department of Hospital and Clinical Pharmacy, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Thijs H. Oude Munnink
1Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Helle-Brit Fiebrich
1Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Wim J. Sluiter
2Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Thera P. Links
2Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Annemiek M.E. Walenkamp
1Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Elisabeth G.E. de Vries
1Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 55, Issue 7
July 1, 2014
Everolimus Reduces 89Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors
Sophie J. van Asselt, Sjoukje F. Oosting, Adrienne H. Brouwers, Alfons H.H. Bongaerts, Johan R. de Jong, Marjolijn N. Lub-de Hooge, Thijs H. Oude Munnink, Helle-Brit Fiebrich, Wim J. Sluiter, Thera P. Links, Annemiek M.E. Walenkamp, Elisabeth G.E. de Vries
Journal of Nuclear Medicine Jul 2014, 55 (7) 1087-1092; DOI: 10.2967/jnumed.113.129056
Everolimus Reduces 89Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors
Sophie J. van Asselt, Sjoukje F. Oosting, Adrienne H. Brouwers, Alfons H.H. Bongaerts, Johan R. de Jong, Marjolijn N. Lub-de Hooge, Thijs H. Oude Munnink, Helle-Brit Fiebrich, Wim J. Sluiter, Thera P. Links, Annemiek M.E. Walenkamp, Elisabeth G.E. de Vries
Journal of Nuclear Medicine Jul 2014, 55 (7) 1087-1092; DOI: 10.2967/jnumed.113.129056
Jump to section
Related Articles
Cited By...
- PET Imaging of Receptor Tyrosine Kinases in Cancer
- Molecular Imaging in Cancer Drug Development
- Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study
- 89Zr-Bevacizumab PET: Potential Early Indicator of Everolimus Efficacy in Patients with Metastatic Renal Cell Carcinoma
- 89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease
- Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature
- Predictive factors of response to mTOR inhibitors in neuroendocrine tumours
- Molecular Imaging of Post-Src Inhibition Tumor Signatures for Guiding Dasatinib Combination Therapy
- TGF-{beta} Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET
- Antibody Positron Emission Tomography Imaging in Anticancer Drug Development
- 89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment